Reata Pharmaceuticals (RETA +10.9%) is up out the gate on reports that Amgen (AMGN -3.9%) is mulling acquiring assets in the space.
Reata's lead candidate is bardoxolone methyl, in late-stage development for a kidney disorder called Alport syndrome, connective tissue disease-pulmonary arterial hypertension and focal segmental glomerulosclerosis.
Another late-stage candidate is omaveloxolone for a degenerative neuromuscular disorder called Friedreich's ataxia.
Short interest 14%
Alert set for breakout above $227 for possible long entry.
Company profile
Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.
Reata's lead candidate is bardoxolone methyl, in late-stage development for a kidney disorder called Alport syndrome, connective tissue disease-pulmonary arterial hypertension and focal segmental glomerulosclerosis.
Another late-stage candidate is omaveloxolone for a degenerative neuromuscular disorder called Friedreich's ataxia.
Short interest 14%
Alert set for breakout above $227 for possible long entry.
Company profile
Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.